The European Medicines Agency (EMA) has approved the antibody for two cancers following positive results from the TROPION-Lung01 and TROPION-Breast01 trials. Credit: martinbertrand.fr via ShutterStock.

Two marketing authorisation applications for Daiichi Sankyo and AstraZeneca’s jointly developed Dato-DXd (datopotamab deruxtecan) have been greenlighted by the European Medicines Agency (EMA), in two distinct cancer types.

One application is for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment. This submission was based on results from the Phase III TROPION-Lung01 trial (NCT04656652). Lung cancer patients treated with Dato-DXd were compared to those taking the chemotherapy drug docetaxel, the current standard of care.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The other application is for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2-negative breast cancer who have progressed on and are not suitable for endocrine therapy and received at least one additional systemic therapy. This application was based on results from the Phase III TROPION-Breast01 trial (NCT05104866).

Results from both trials indicated that Dato-DXd significantly improved progression-free survival compared to chemotherapy in both cancer types.

It’s been a positive start to the year for the companies regarding Dato-DXd. In February, the US Food and Drug Administration (FDA) accepted Dato-DXd’s filing for review for the treatment of patients with locally advanced or metastatic NSCLC who have received prior systemic therapy. A decision is anticipated later this year, with a Prescription Drug User Free Act (PDUFA) date scheduled for 20 December 2024. The companies have also submitted a biologics license application to the FDA for breast cancer treatment.

See Also:

Dato-DXd is a TROP2-directed antibody-drug conjugate (ADC). TROP2 is a protein highly expressed in many types of lung and breast cancers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Daiichi Sankyo’s three lead ADCs, which it is developing with pharma partners—Enhertu (trastuzumab deruxtecan), patritumab deruxtecan (HER3-Dxd), and Dato-Dxd—are expected to hold a significant chunk of the ADC market. The combined global sales of these three drugs are predicted to reach $13bn by 2029, according to GlobalData’s Intelligence Centre.

GlobalData is the parent company of Pharmaceutical Technology.

In the announcement accompanying the validations, executive vice president for oncology R&D at AstraZeneca Susan Galbraith said: “Today’s dual validation of our applications in lung and breast cancers brings this potential medicine a meaningful step closer to redefining treatment expectations for patients with two of the most common cancers in Europe.”